Avatrombopag

Chemical structure of Avatrombopag

Avatrombopag is a medication used primarily to treat thrombocytopenia, a condition characterized by abnormally low levels of platelets in the blood. It is particularly used in patients with chronic liver disease who are scheduled to undergo a medical or dental procedure, as well as in patients with chronic immune thrombocytopenic purpura (ITP).

Mechanism of Action

Avatrombopag is a thrombopoietin receptor agonist. It works by stimulating the production of platelets in the bone marrow. The drug binds to the thrombopoietin receptor on the surface of megakaryocytes and their precursors, promoting their proliferation and differentiation into platelets. This mechanism helps increase platelet counts in patients with thrombocytopenia.

Clinical Use

Avatrombopag is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. It is also used in adult patients with chronic immune thrombocytopenic purpura who have had an insufficient response to previous treatment.

Administration

Avatrombopag is administered orally. The dosage and duration of treatment depend on the specific condition being treated and the patient's platelet count. It is important for patients to follow their healthcare provider's instructions regarding dosage and administration.

Side Effects

Common side effects of avatrombopag include headache, fatigue, and nausea. Serious side effects may include thromboembolic events, such as deep vein thrombosis or pulmonary embolism. Patients should be monitored for signs of increased platelet counts and potential thrombotic complications.

Pharmacokinetics

Avatrombopag is absorbed in the gastrointestinal tract and reaches peak plasma concentrations approximately 3 to 6 hours after administration. It is metabolized primarily in the liver and excreted in the feces. The half-life of avatrombopag is approximately 19 hours, allowing for once-daily dosing.

Development and Approval

Avatrombopag was developed by Eisai Co., Ltd., a Japanese pharmaceutical company. It was approved by the U.S. Food and Drug Administration (FDA) in 2018 for the treatment of thrombocytopenia in patients with chronic liver disease scheduled to undergo a procedure. It was later approved for use in patients with chronic immune thrombocytopenic purpura.

Related Pages

• Thrombocytopenia
• Thrombopoietin receptor agonist
• Chronic liver disease
• Immune thrombocytopenic purpura